These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38143794)

  • 1. The benefits of GLP1 receptors in cardiovascular diseases.
    Ferhatbegović L; Mršić D; Macić-Džanković A
    Front Clin Diabetes Healthc; 2023; 4():1293926. PubMed ID: 38143794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.
    Ma X; Liu Z; Ilyas I; Little PJ; Kamato D; Sahebka A; Chen Z; Luo S; Zheng X; Weng J; Xu S
    Int J Biol Sci; 2021; 17(8):2050-2068. PubMed ID: 34131405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
    Varin EM; McLean BA; Lovshin JA
    Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
    Madsbad S; Holst JJ
    Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.
    Helmstädter J; Keppeler K; Küster L; Münzel T; Daiber A; Steven S
    Br J Pharmacol; 2022 Feb; 179(4):659-676. PubMed ID: 33764504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS.
    Blonde L; Fonseca V
    Endocr Pract; 2018 Aug; ():. PubMed ID: 30084684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.
    Gomes DA; Presume J; de Araújo Gonçalves P; Almeida MS; Mendes M; Ferreira J
    Cardiovasc Drugs Ther; 2024 Jan; ():. PubMed ID: 38214869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.
    Davies MJ; Drexel H; Jornayvaz FR; Pataky Z; Seferović PM; Wanner C
    Cardiovasc Diabetol; 2022 Aug; 21(1):144. PubMed ID: 35927730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
    Mora PF; Johnson EL
    Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes.
    d'Aquino AI; Maikawa CL; Nguyen LT; Lu K; Hall IA; Jons CK; Kasse CM; Yan J; Prossnitz AN; Chang E; Baker SW; Hovgaard L; Steensgaard DB; Andersen HB; Simonsen L; Appel EA
    bioRxiv; 2023 Jul; ():. PubMed ID: 36778223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.
    Cornell S
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):17-27. PubMed ID: 32910490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.